Wenyi Lu

ORCID

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 8

Top Venues

Leukemia

Cancer immunology, immunotherapy : CII

Cell transplantation

This page only lists publications with an associated author ORCID identifier.

Publications

Wenyi Lu, Hairong Lyu, Xia Xiao, Xue Bai, Meng Zhang, Jiaxi Wang, Yedi Pu, Juanxia Meng, Xiaomei Zhang, Haibo Zhu, Ting Yuan, Bing Wang, Xin Jin, Xinping Cao, Zhao Wang, Tianle Xie, Haotian Meng, Alexey V Stepanov, Alexander G Gabibov, Yuxin An, Rui Sun, Yu Zhang, Mikhail A Maschan, Zunmin Zhu, Hongkai Zhang, Mingfeng Zhao
Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation. Leukemia 38 (6) (2024)
Wenyi Lu, Hairong Lyu, Xia Xiao, Xue Bai, Meng Zhang, Jiaxi Wang, Yedi Pu, Juanxia Meng, Xiaomei Zhang, Haibo Zhu, Ting Yuan, Bing Wang, Xin Jin, Xinping Cao, Zhao Wang, Tianle Xie, Haotian Meng, Alexey V Stepanov, Alexander G Gabibov, Yuxin An, Rui Sun, Yu Zhang, Mikhail A Maschan, Zunmin Zhu, Hongkai Zhang, Mingfeng Zhao
Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation. Leukemia 38 (6) (2024)
Wenyi Lu, Hairong Lyu, Xia Xiao, Xue Bai, Meng Zhang, Jiaxi Wang, Yedi Pu, Juanxia Meng, Xiaomei Zhang, Haibo Zhu, Ting Yuan, Bing Wang, Xin Jin, Xinping Cao, Zhao Wang, Tianle Xie, Haotian Meng, Alexey V Stepanov, Alexander G Gabibov, Yuxin An, Rui Sun, Yu Zhang, Mikhail A Maschan, Zunmin Zhu, Hongkai Zhang, Mingfeng Zhao
Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation. Leukemia 38 (6) (2024)
Wenyi Lu, Hairong Lyu, Xia Xiao, Xue Bai, Meng Zhang, Jiaxi Wang, Yedi Pu, Juanxia Meng, Xiaomei Zhang, Haibo Zhu, Ting Yuan, Bing Wang, Xin Jin, Xinping Cao, Zhao Wang, Tianle Xie, Haotian Meng, Alexey V Stepanov, Alexander G Gabibov, Yuxin An, Rui Sun, Yu Zhang, Mikhail A Maschan, Zunmin Zhu, Hongkai Zhang, Mingfeng Zhao
Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation. Leukemia (2024)
Wenyi Lu, Hairong Lyu, Xia Xiao, Xue Bai, Meng Zhang, Jiaxi Wang, Yedi Pu, Juanxia Meng, Xiaomei Zhang, Haibo Zhu, Ting Yuan, Bing Wang, Xin Jin, Xinping Cao, Zhao Wang, Tianle Xie, Haotian Meng, Alexey V Stepanov, Alexander G Gabibov, Yuxin An, Rui Sun, Yu Zhang, Mikhail A Maschan, Zunmin Zhu, Hongkai Zhang, Mingfeng Zhao
Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation. Leukemia 38 (6) (2024)
Wenyi Lu, Hairong Lyu, Xia Xiao, Xue Bai, Meng Zhang, Jiaxi Wang, Yedi Pu, Juanxia Meng, Xiaomei Zhang, Haibo Zhu, Ting Yuan, Bing Wang, Xin Jin, Xinping Cao, Zhao Wang, Tianle Xie, Haotian Meng, Alexey V Stepanov, Alexander G Gabibov, Yuxin An, Rui Sun, Yu Zhang, Mikhail A Maschan, Zunmin Zhu, Hongkai Zhang, Mingfeng Zhao
Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation. Leukemia 38 (6) (2024)
Wenyi Lu, Xin Jin, Hairong Lyu, Xue Bai, Haibo Zhu, Xin Li, Xia Xiao, Juanxia Meng, Ting Yuan, Qing Li, Juan Mu, Cuicui Lyu, Yili Jiang, Yunxiong Wei, Xia Xiong, Meng Zhang, Mingfeng Zhao
A Prospective Trial Comparing Haploidentical Donor Transplantation With Cord Blood Versus HLA-Matched Sibling Donor Transplantation for Hematologic Malignancy Patients. Cell transplantation 31 (2022)
Wenyi Lu, Yunxiong Wei, Yaqing Cao, Xia Xiao, Qing Li, Hairong Lyu, Yili Jiang, Huan Zhang, Xin Li, Yanyu Jiang, Juanxia Meng, Ting Yuan, Haibo Zhu, Xiaoyuan He, Xin Jin, Rui Sun, Tao Sui, Kaiqi Liu, Mingfeng Zhao
CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease. Cancer immunology, immunotherapy : CII 70 (12) (2021)

Wenyi Lu.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Wenyi Lu